Clinical Trials Logo

Atrophy clinical trials

View clinical trials related to Atrophy.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06443476 Recruiting - Clinical trials for Posterior Atrophic Mandible

Tenting Abutment Technique Versus Screw"Tent-Pole" Technique for Augmentation of Posterior Atrophic Mandible

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

To evaluate a novel method using a designed tenting abutment to reduce number of surgeries and the edentulous healing period is shortened. In addition, to prevent vertical and horizontal collapse of the bone graft and minimizes resorption of the bone graft during the healing the atrophic posterior mandible. The tent pole provides excellent mechanical properties; stability & fixation, yet very poor features to preserve the integrity of the soft tissue. Using the tenting abutment technique will help preserve the soft tissue and decrease the amount of dehiscence that might accompany the use of the tent pole.

NCT ID: NCT06434441 Recruiting - Bone Atrophy Clinical Trials

Bone Augmentation Using Calvarial Versus Iliac Crest Bone Blocks.

Start date: August 10, 2023
Phase: N/A
Study type: Interventional

This study aims to evaluate and compare the quantity of the radiographic horizontal bone gain of severely deficient complete maxillary ridges reconstructed by bone block harvest from the iliac crest versus the calvarial bones

NCT ID: NCT06421831 Recruiting - Clinical trials for Spinal Muscular Atrophy Type 3

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients

Start date: May 10, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 3 (SMA 3) patients.

NCT ID: NCT06419322 Recruiting - Clinical trials for Spinal Muscular Atrophy

Acceptability, Feasibility, Safety and Efficacy of a Optimized Rehabilitation Program for Treated Patients With Spinal Muscular Atrophy (SMA).

ACE SMA
Start date: June 2024
Phase: N/A
Study type: Interventional

The goal of this study is to investigate the acceptability, feasibility, safety and efficacy of an optimized rehabilitation program for treated patients with spinal muscular atrophy (SMA) compared to the current rehabilitation program in the United Kingdom. The aim is to provide patients with more hands on physiotherapy and access to rehabilitation devices at home to support parents currently providing rehabilitation on their own.

NCT ID: NCT06411912 Recruiting - Clinical trials for Spinal and Bulbar Muscular Atrophy

A Study of NIDO-361 in Patients With SBMA

PIONEER KD
Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and efficacy of NIDO-361 in adult patients with Spinal and Bulbar Muscular Atrophy (SBMA).

NCT ID: NCT06394232 Recruiting - Clinical trials for Age-Related Macular Degeneration

Safety & Efficacy of Eyecyte-RPEā„¢ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.

Start date: June 4, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD). The main questions it aims to answer are: - Safety and tolerability of the novel stem cell formulation - Potential efficacy of the novel stem cell formulation Participants will receive a single subretinal injection in their study eye and followed up for safety. This is an India only study and the product is developed indigenously.

NCT ID: NCT06370143 Recruiting - Gastric Cancer Clinical Trials

A Study Collecting Health Information to Understand and Prevent Gastric Cancer

Start date: April 11, 2024
Phase:
Study type: Observational

The purpose of this study is to create a registry of participants with precursor lesions for gastric cancer, including gastric atrophy, intestinal metaplasia, and dysplasia. Normal controls and individuals with gastric cancer for comparison of baseline characteristics will also be enrolled.

NCT ID: NCT06368076 Recruiting - Clinical trials for Spinal Muscular Atrophy

High-intensity Interval Training in Patients With Spinal Muscular Atrophy

Start date: January 9, 2024
Phase: N/A
Study type: Interventional

Patients with spinal muscular atrophy who are wheelchair users often experience lower back - and gluteal pain, reduced sleep quality, constipation and reduced quality of life - symptoms that regular exercise could potentially alleviate. However, only very little research has been done on exercise for patients who are wheelchair users. The aim of this study is to explore the impact of cycle exercise on patients with spinal muscular atrophy.

NCT ID: NCT06324825 Recruiting - Clinical trials for Atrophic Gastritis With Low-grade Intraepithelial Neoplasia

Fuzheng Nizeng Formula for Chronic Atrophic Gastritis With Low-grade Intraepithelial Neoplasia, a Multicenter Randomized Controlled Trial

Start date: October 24, 2022
Phase: N/A
Study type: Interventional

Fuzheng Nizeng Formula (FZNZ) is derived from the classic formula Liujunzi Decoction. Former pilot study found that FZNZ promoted the recovery of gastric atrophy and relieve the relative symptoms. This study is to evaluate its efficacy for chronic atrophic gastritis with low-grade intraepithelial neoplasia, compared with positive control Molduodan granule.

NCT ID: NCT06319768 Recruiting - Atrophic Acne Scar Clinical Trials

Efficacy of Intralesional Injection of Pentoxifylline, Platelet-Rich Plasma, and Combined Pentoxifylline With Platelet-Rich Plasma in Patients With Atrophic Acne Scars

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

Platelet-rich plasma (PRP) is an Acne vulgaris is a common chronic inflammatory skin disorder. It is the eighth most prevalent disease worldwide with a prevalence of 9.4%. Acne scar is one of the most persistent complications of acne, causes marked psychological stress to the patient . The process of acne scar formation can be broadly divided into two stages: increased tissue formation and loss or damage of tissue, corresponding to keloid or hypertrophic scar and atrophic scar, respectively. The ultimate severity of acne scars is correlated with acne grade and the delay in treatment of active disease. The atrophic scars include three subtypes: icepick or V-shaped, rolling or M-shaped, and boxcar or U-shaped scars. Among atrophic scars, the ice pick type represents 60%-70%; the boxcar type represents 20%-30%; and the rolling type represents 15%-25% (Salameh and Shumaker, 2022). According to the qualitative scarring grading system, a macular acne scar type also exists, which clinically shows erythematous, hyperpigmented, or hypopigmented flat marks. autologous blood product containing high concentrations of platelets in a small volume of plasma. PRP has been utilized in the treatment of orthopedic, musculoskeletal, and maxillofacial conditions for many years, it has only recently gained popularity in dermatology. PRP contains various growth factors, including platelet-derived growth factor (PDGF), transforming growth factor (TFG), vascular endothelial growth factor (VEGF), and insulin-like growth factor (IGF). These growth factors stimulate tissue remodeling and are associated with enhanced healing through the attraction of macrophages, upregulation of collagen synthesis, and promotion of tissue regeneration. Moreover, platelet-derived growth factor (PDGF) was shown to promote wound healing, angiogenesis, and tissue remodeling.